secwatch / observer

8-K filed August 12, 2024, 7:59 PM ET ticker FRST CIK 0001325670

other material confidence high sentiment negative materiality 0.80

Primis Financial says SEC OK'd corrected accounting; expects ~$30M net income reduction, filings by end of August

Primis Financial Corp.

SEC non-objection on Aug 9 to multi-unit accounting for consumer loan program; company to restate 2023 and 2024 interim results.
Preliminary cumulative net income reduction of ~$30 million over prior periods through Q2 2024, primarily timing differences.
At June 30, 2024, 42% of portfolio in promotional period with ~$15M deferred interest; 72% of promotions expire in next three quarters.
Company continues SEC consultation for single-unit accounting; no assurance of success.
Anticipates first delayed filings (Form 10-K/Q) around end of August 2024.

item 8.01 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-24-088407
form_type: 8-K
ticker: FRST
cik: 0001325670
company_name: Primis Financial Corp.
filed_at: 2024-08-12T23:59:59+00:00
discovered_at: 2026-05-14T18:03:12.590419+00:00
generated_at: 2026-05-31T09:58:51.810833+00:00
sec_items: ["8.01", "7.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-24-088407
json_url: https://secwatch.observer/filing/0001104659-24-088407.json
markdown_url: https://secwatch.observer/filing/0001104659-24-088407.md
text_url: https://secwatch.observer/filing/0001104659-24-088407.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1325670/000110465924088407/0001104659-24-088407-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1325670/000110465924088407/tm2421467d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001104659-24-088407

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.